November 29, 2016 - By Adrian Mccoy
Wells Fargo downgraded shares of Advanced Accel (AAAP) from a Outperform rating to a Market Perform rating in a an analyst note made public on Tuesday morning.
Out of 3 analysts covering Advanced Accel… (AAAP), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. $36 is the highest target while $36 is the lowest. The $36 average target is 22.91% above today’s ($29.29) stock price. Advanced Accel… has been the topic of 3 analyst reports since March 9, 2016 according to StockzIntelligence Inc. The firm has “Neutral” rating given on Wednesday, March 16 by Citigroup. The stock of Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The firm earned “Outperform” rating on Tuesday, October 18 by Wells Fargo.
About 151,629 shares traded hands or 72.24% up from the average. Advanced Accelerator Application SA(ADR) (AAAP) has declined 13.07% since April 26, 2016 and is downtrending. It has underperformed by 18.33% the S&P500.
Analysts await Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) to report earnings on December, 8. They expect $-0.09 earnings per share, down 28.57% or $0.02 from last year’s $-0.07 per share. After $-0.04 actual earnings per share reported by Advanced Accelerator Application SA(ADR) for the previous quarter, Wall Street now forecasts 125.00% negative EPS growth.
Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company has a market cap of $1.04 billion. The Firm develops, produces and commercializes molecular nuclear medicine , diagnostic and therapeutic products. It currently has negative earnings. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer.
According to Zacks Investment Research, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France.”
Advanced Accelerator Applications S.A., incorporated on March 1, 2002, is a radiopharmaceutical company. The Firm develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Firm is engaged in developing its therapeutic candidate, Lutathera, which is a compound for the treatment of neuro endocrine tumors (NETs). It has a portfolio of approximately six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. The Company’s products in clinical development include Lutathera, Somakit and Annexin V-128. The Company’s commercial products include Gluscan/Gluscan 500/Barnascan, IASOflu, IASOdopa, DOPAVIEW, IASOcholine, AAACholine, MIBITEC/Adamibi and Leukokit.
More notable recent Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) news were published by: Marketwatch.com which released: “Advanced Accelerator Applications downgraded to market perform from outperform …” on December 29, 2013, also Quotes.Wsj.com with their article: “DOW JONES, A NEWS CORP COMPANY” published on January 31, 2015, Benzinga.com published: “10 Stocks With Three-Day Increasing Volume” on November 29, 2016. More interesting news about Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) were released by: Nasdaq.com and their article: “Mid-Morning Market Update: Markets Open Lower; Edwards Lifesciences To Buy …” published on November 28, 2016 as well as Nasdaq.com‘s news article titled: “Mid-Afternoon Market Update: Fang Holdings Drops Following Q3 Results; Recro …” with publication date: November 28, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy